Odomzo approved for recurring basal cell carcinoma

July 25, 2015

(HealthDay)—Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat basal cell carcinoma skin cancer that has returned despite surgery or radiation.

The treatment is sanctioned for people who are not candidates for additional surgery or radiation.

Basal cell carcinoma accounts for about 80 percent of skin cancers that are not melanoma, a more deadly form of the disease. Basal cell starts in the top layer of skin, usually in areas that are most exposed to the sun, the agency said Friday in a news release.

The once-daily pill is designed to inhibit a process that promotes the growth of .

The drug's label includes a boxed warning that it may cause death or severe birth defects in a growing fetus. Women who may become pregnant should verify pregnancy status before taking the drug. And both males and females who take Odomzo are advised to use contraception, the agency said.

The drug was evaluated in a clinical study involving 66 people. Some 58 percent of people treated with 200 milligrams of Odomzo had their tumors shrink or disappear, the FDA said. The most common side effects included , hair loss, distorted taste, fatigue, nausea, muscle and bone pain, diarrhea and weight loss. More serious musculoskeletal issues also are possible.

Odomzo is marketed by Novartis, based in East Hanover, N.J.

Explore further: FDA approves Roche skin cancer drug Erivedge

More information: The FDA has more about this approval.

Related Stories

FDA approves Roche skin cancer drug Erivedge

January 30, 2012
(AP) -- Federal regulators on Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

Mekinist plus tafinlar approved for late-stage melanoma

January 10, 2014
(HealthDay)—The U.S. Food and Drug Administration on Friday approved Mekinist for use with another drug, Tafinlar, to treat advanced melanoma that is spreading or cannot be removed by surgery.

Orbactiv approved for drug-resistant skin infections

August 7, 2014
(HealthDay)—The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.

Afinitor approved for advanced breast cancer

July 23, 2012
(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration ...

Opdivo approval expanded to include lung cancer

March 4, 2015
(HealthDay)—U.S. Food and Drug Administration approval of Opdivo (nivolumab) has been expanded to include advanced non-small cell lung cancer (NSCLC), the agency said Wednesday in a news release.

Farydak approved for multiple myeloma

February 24, 2015
(HealthDay)—Farydak (panobinostat) has been approved by the U.S. Food and Drug Administration to treat multiple myeloma, a cancer of the blood.

Recommended for you

Complex inhalers prevent patients from taking medicine

February 23, 2018
Respiratory disease patients with arthritis could struggle to manage their conditions because their inhalers are too fiddly for them to use, University of Bath research has found.

Opioid abuse leads to heroin use and a hepatitis C epidemic, researcher says

February 22, 2018
Heroin is worse than other drugs because people inject it much sooner, potentially resulting in increased risk of injection-related epidemics such as hepatitis C and HIV, a Keck School of Medicine of USC study shows.

Opioid addiction treatment behind bars reduced post-incarceration overdose deaths in RI

February 14, 2018
A treatment program for opioid addiction launched by the Rhode Island Department of Corrections was associated with a significant drop in post-incarceration drug overdose deaths and contributed to an overall drop in overdose ...

Heroin vaccine blocks lethal overdose

February 14, 2018
Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug. Their research, published ...

Study shows NIH spent >$100 billion on basic science for new medicines

February 12, 2018
Federally funded research contributed to the science underlying all new medicines approved by the FDA over the past six years, according to a new study by Bentley University.

Opioid use increases risk of serious infections

February 12, 2018
Opioid users have a significantly increased risk of infections severe enough to require treatment at the hospital, such as pneumonia and meningitis, as compared to people who don't use opioids.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.